A
Alamar Biosciences
Improving human health by developing innovative immunoassays and engineering picomolar affinity antibodies
About Alamar Biosciences
Alamar BioSciences is a biotechnology startup that operates in the field of proteomics, the large-scale study of proteins. The company has developed a groundbreaking technology called NULISA™, which has the ability to detect and measure proteins in the human body with unprecedented sensitivity and range. This technology has the potential to revolutionize our understanding of the role of proteins in health and disease, and could significantly improve the early detection and treatment of various diseases.
Alamar's primary clients are researchers and clinicians who are interested in profiling and validating clinically relevant protein biomarkers. These biomarkers can be used to develop new diagnostic tests and treatments for a wide range of diseases. The company's business model is based on providing these clients with access to its NULISA™ technology and ARGO™ system, a fully automated, high-throughput precision proteomics platform.
The company generates revenue by charging for the use of its technology and platform. This includes fees for the detection and quantification of low-abundance proteins, as well as for the ability to focus on a single target or multiplex hundreds to thousands of targets in a single experiment. The company's technology also reduces the need for technical expertise, which could make it more attractive to potential clients.
In summary, Alamar BioSciences is a promising startup that is poised to make a significant impact in the field of proteomics. Its innovative technology could transform the way we understand and treat diseases, and its business model has the potential to generate substantial revenue.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2026
- Outcome tier
- Unicorn$1–10B valuation tier
News
Open roles
Alamar Biosciences in the Hayward ecosystem
The Alamar Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Alzheimer's Drug Discovery Foundation
Series A5 investors entered at this stage
Qiming Venture Partners
Sherpa Venture Partners
Samsara BioCapital
Illumina Ventures
Morningside Venture Partners
Series B and later4 investors entered at this stage
- IVIllumina Ventures
- MPMorningside Venture Partners
- SPSherpa Venture Partners
- SBSamsara BioCapital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
5 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alamar Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alamar Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

